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wherein R is selected from alkyl, alkenyl, aryl, CH-OH,
-CH-O-alkyl, -CH2-O-aryl, -CHOPOH,
-CH-O-carbohydrate, -CH-NH-peptide, or
-CH-O-peptide;
wherein R is selected from hydroxy, -O-carbohydrate,
-NH-peptide,
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wherein R is selected from H, halogen, lower alkyl,
lower alkenyl, lower haloalkyl, lower haloalkenyl,
amino, mono- or di-lower alkylamino;
wherein R is Selected from amino, hydroxy, alkoxy, or
halogen; and
wherein Rs is H or amino. The compounds of formula
(I) are useful as antiviral and antineoplastic agents
and the compounds of formula (II) are useful as plant
growth inhibitors and herbicides. Also disclosed is a
method for preparing the heavily fluorinated Sugars
of the present invention which utilizes inexpensive
Starting materials which incorporate the desired
number of fluorine moieties and a new reagent,
benzyloxymethylzinc bromide, for introducing the
5'-hydroxymethyl moiety. The synthetic method of
the present invention is advantageous in that it does
not require late Stage fluorination Step.

24 Claims, 2 Drawing Sheets
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HEAVILY FLUORINATED SUGAR ANALOGS

SUMMARY OF THE INVENTION

RELATED APPLICATION

It is an object of the present invention to provide heavily
fluorinated Sugar analogs containing a tetrafluoroethylene

This application claims priority under 35 U.S.C. S 119(e)

to U.S. provisional application Ser. No. 60/026,459, filed
Sep. 25, 1996.

unit (-CFCF-) in the Sugar nucleus of ribose based

nucleoside analogs and a hexafluorotrimethylene unit

BACKGROUND OF THE INVENTION
1. Field of the Invention

The present invention relates to heavily fluorinated Sugar
molecules, a method for the preparation thereof, and their
use as antiviral and antineoplastic agents, glycosidase
inhibitors, plant growth regulators and herbicides, and as
intermediates for the preparation of heavily fluorinated
oligo- and polysaccharides. The present invention also
relates to a new starting material for the preparation of the
heavily fluorinated Sugar analogs of the present invention.
2. Description of the Prior Art
Nucleotides perform a large number of functions for
living organisms. For example, nucleotides Serve as the
basic building blocks for RNA and DNA, store and transfer
the essential chemical energy that propels metabolism, acti
Vate chemical bonds for enzymatic reactions, control
glycolysis, regulate the process of cell to cell
communication, and perform a large number of other essen
tial tasks. Because they are crucial to Such a wide variety of
essential biochemical tasks, nature has designed exquisitely
Selective enzymes for this class of compounds.
Neoplastic or viral diseases, in contrast to bacterial
diseases, have proved difficult to treat. While bacterial
diseases have a number of biochemical processes that are
distinct to the organism, Viruses use the cellular machinery
of the infected host cell, and there are relatively few virus
Specific processes that can be inhibited Selectively.
Similarly, tumor cells are mutated variants of normal cells
and rely on many of the same biochemical pathways.
Therefore, chemotherapies targeted for these diseases are
often highly toxic due to the lack of selectivity of the
compound for diseased cells. One characteristic that marks
both virally infected cells and tumor cells is their propensity
for rapid growth. Since growth involves synthesis of DNA
and RNA, these cells require a greater flux of nucleotides in
comparison to normal cells, and often the diseased cell
contains enzymes which are leSS Selective for nucleotides
than their counterparts in normal cells. Therefore, nucleotide
analogs may act as Substrates for the disease State enzymes,
while they are virtually ignored by normal enzymes. This is
the rationale for design of therapeutic nucleotide or nucleo
side analogs, such as IUDR, trifluorothymidine, AZT, Ara
A, ribavirin, acyclovir, ganciclovir, gemcitabine, MDL-101,
731. Research on derivatives of nucleoside and nucleotide

analogs continues to be intense. AS the above examples
Show, modification on the base and Sugar moieties is poS
Sible and in Some case, desirable. Recently, there has been
a great deal of interest in fluorinated derivatives in which
fluorine is incorporated into the Sugar nucleus. Gemcitabine

(-CFCFCF-) in the Sugar nucleus of hexose based
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nucleoside analogs.
Another object of the present invention is to provide a
synthetic method for easily obtaining the heavily fluorinated
Sugar analogs which provides for a higher degree of fluo
rination than is obtainable in the prior art methods, and
which does not require a fluorination Step at or near the end
of the synthesis.
Another object of the present invention is to provide a
novel Starting material for the production of heavily fluori
nated SugarS.
Yet another object of the present invention is to provide a
method for the treatment of viral and neoplastic diseases by
administering a pharmaceutically effective amount of the
heavily fluorinated nucleoside analogs according to the
present invention to a patient in need thereof.
A further object of the present invention is to provide for
a method of inhibiting glycosidases by administering a
pharmaceutically effective amount of the heavily fluorinated
nucleoside analogs according to the present invention to a
patient in need thereof, Such as a patient with diabetes
mellitus.
BRIEF DESCRIPTION OF THE DRAWINGS

35

FIG. 1 shows an X-ray crystal determination of compound
2.

FIG.2 shows an X-ray crystal determination of compound
7.
40

DETAILED DESCRIPTION OF THE
INVENTION
45

The objects of the present invention are provided by the
heavily fluorinated Sugar analogs of formula:
R1

substituents. See also U.S. Pat. Nos. 4.963,662 (Matthes et
al.), 5,153,180 (Matthes et al.), and 4,762,823 (Watannabe et
al.).
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(Eli Lilly) is now heading to market as an antiviral as well
as a treatment for non Small cell lung cancer. Pancreatic
cancer Studies are also underway. The fluorine Substituents
help Stabilize the Sugar against glycolysis and improve the
oral bioavailability of the drug. MDL 101,731 is active
against breast, prostate, and colon cancers. Although nucleo
Side analogs containing fluorine in the Sugar nucleus are
known in the art, such as gemcitabine and MDL-101,731,
the prior art compounds only contain one or two fluorine
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wherein R is selected from alkyl, alkenyl, aryl, CHOH,
-CH2-O-alkyl, -CH2-O-aryl, -CHOPOH,
-CH-O-carbohydrate, -CH-NH-peptide, or
-CH-O-peptide;
wherein R is selected from hydroxy, -O-carbohydrate,
-NH-peptide,
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wherein R is Selected from H, halogen, lower alkyl,
lower alkenyl, lower haloalkyl, lower haloalkenyl,
amino, mono- or di-lower alkylamino;
wherein R is Selected from amino, hydroxy, alkoxy, or
halogen; and
wherein R is H or amino.
The compounds according to the present invention are
intended to encompass all Stereoisomers and mixtures

25

thereof.

Halogen includes fluorine, chlorine, bromine, or iodine.
Lower alkyl includes branched or Straight chain alkyl groups
having from 1 to about 10 carbon atoms. Lower haloalkyl
includes branched or Straight chain alkyl groups having from
1 to about 10 carbon atoms mono-, di-, or trisubstituted, or

higher, by fluorine, chlorine, bromine, or iodine, Such as
monofluoromethyl, difluoromethyl, trifluoromethyl, etc.
Lower alkenyl includes branched or Straight chain alkenyl
groups having from 1 to about 10 carbon atoms, having one
or more carbon-carbon double bonds. Lower haloalkenyl
includes branched or Straight chain alkenyl groups having
from 1 to about 10 carbon atoms having one or more

35

carbon-carbon double bonds mono-, di-, or trisubstituted, or

higher, by fluorine, chlorine, bromine, or iodine. Typical
carbohydrates in the definition of R and R include, for
example, mono-, di-, oligo-, or polysaccharides, Such as
glucose, galactose, and the like. Typical peptides in the
definition of R and R2 include, for example, naturally
occurring or Synthetic amino acids, or di-, oligo-, or
polypeptides, derived from naturally occurring or Synthetic

40
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amino acids.

The compounds according to the present invention

according to formula (I) find utility as antiviral and antine

oplastic agents, and as glycosidase inhibitors. The com
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pounds according to formula (II) are useful as plant growth
inhibitors, glycosidase inhibitors, and herbicides.
A further aspect of the present invention relates to pro
ceSSes for preparing heavily fluorinated Sugars and Starting
materials and intermediates useful therein.
It will be understood that the reactions in which the novel

heavily fluorinated carbohydrates according to the present
invention are coupled with the bases are frequently of a
nature Such that the hydroxy groups should be protected to
keep them from reacting with the base, or being decomposed
in Some manner. The protecting groups are chosen from the
groupS used in Synthetic organic chemistry for the purpose.
Chemists are accustomed to choosing groups which can be
efficiently placed on hydroxy groups, and which can be
easily removed when the desired reaction is complete.
Suitable groups are described in Standard textbooks, Such as
Chapter 3 of Protective Groups in Organic Chemistry,

55

60
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4
McOmie, Ed., Plenum Press, New York (1973); and Chapter
2 of Protective Groups in Organic Synthesis, Greene, John
Wiley & Sons, New York (1981).
Typical hydroxy-protecting groups include formyl,
2-chloroacetyl, benzyl, diphenylmethyl, triphenylmethyl,
4-nitrobenzyl, phenoxycarbonyl, t-butyl, methoxymethyl,
tetrahydropy ranyl, ally l, tetrahydro thie nyl,
2-methoxyethoxymethyl, methoxyacetyl, phenoxyacetyl,
isobutyryl, ethoxycarbonyl, benzyloxycarbonyl and the like.
Sillyl hydroxy-protecting groups are often particularly
convenient, because most of them are easily cleaved by
contact with water or an alcohol. Such groups include
especially trimethylsilyl, as well as isopropyldimethylsilyl,
methyl diisopropyl Sily l, trii Sopropyl Sillyl,
t-butylidimethylsilyl, and the like.
Heavily fluorinated carbohydrates may have a hydroxy
group at the 1-position of its ring, and in order to react the
heavily fluorinated Sugars with a base to form the heavily
fluorinated nucleoside analogs according to the present
invention, it is necessary to place a leaving group at the
1-position. The leaving groupS used are typical of those used
commonly in organic Synthesis. The preferred leaving
groups are Sulfonates, of which the most preferred is meth
anesulfonate; other typical leaving groups Such as
toluenesulfonate, ethaneSulfonate, isopropanesulfonate,
4-methoxybenzeneSulfonate, 4-nitrobenzeneSulfonate, and
2-chlorobenzenesulfonate. Chloro and bromo may also be
used.
An appropriate leaving group may be placed at the
1-position of the heavily fluorinated Sugar. The preferred
leaving group is methaneSulfonyl, which may be readily
provided by reaction with methanesulfonyl chloride in the
presence of an equivalent amount of a Suitable acid Scav
enger Such as triethylamine and the like. Other Sulfonyl
leaving groups may be provided in the same way by reaction
with the appropriate Sulfonyl halide.
The purine and/or pyrimidine bases used to form the
heavily fluorinated nucleoside analogs according to the
present invention are commonly known to those skilled in
the art, and no discussion of their Synthesis is necessary.
However, the primary amino groups which are present on
Some of the bases should be protected before the base is
coupled with the heavily fluorinated Sugars. The usual
amino-protecting groups are used, including silyl groups
Such as have been discussed, as well as Such typical groups
as t-bu to Xy carbonyl, ben Zylo Xy carbonyl,
4-methoxybenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl,
formyl, acetyl, and the like.
It is often advisable to convert keto oxygen atoms on the
bases to the enol form, in order to make the bases more

highly aromatic and thereby allow more ready attack of the
base by the carbohydrate. It is most convenient to enolize the
oxygens by providing silyl protecting groups for them. The
usual Silyl protecting groups as discussed above are used for
this purpose, also.
The reaction between the protected heavily fluorinated
Sugar and the base may be carried out neat at an elevated
temperature in the range of from about 50 C. to about 200
C. It is also possible to use relatively high-boiling Solvents
for the reaction, Such as dimethylformamide,
dimethylacetamide, hexamethylphosphoramide and the like.
However, if the coupling reaction is carried out under
elevated pressure, to avoid distillation of a low-boiling
Solvent, any convenient inert reaction Solvent can be used.
The coupling reaction may be done at low temperatures if
reaction

initiator,

Such

S

trifluoromethaneSulfonyloxysilane, is used. The usual inert

6,013,790
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S
reaction Solvents, Such as tetrahydrofuran, diethyl ether,
halogenated alkanes Such as chloroform, dichloromethane,
trichloroethane and the like, and aromatics including Such
Solvents as benzene, toluene and the Xylenes may be used.
The final Step of the reaction Sequence is the removal of
the protecting groups. Most silyl protecting groups may be
easily cleaved by contact with water or an alcohol. The
t-butyldimethylsilyl protecting group requires acid
conditions, Such as contact with gaseous hydrogen halide,

-continued
R4

N

N
Rs
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N

wherein n=2 or 3;

may be prepared by converting one of the carboxylic ester

groups of Formula (IV):
loweralkyl-O-C(O)-(CF)-C(O)-O-loweralkyl

(IV)

25

wherein n=2 or 3, to the ketone to yield compounds of

Formula (V):
2-furyl-C(O)-(CF)-C(O)-O-loweralkyl

(V)

and then contacting a compound of Formula (V) with a
reducing agent to form compounds of Formula (VI):
35

(VI)

\N

Heavily fluorinated sugar derivative of Formula (III):

(CF2)

N

wherein R is Selected from H, halogen, lower alkyl,
lower alkenyl, lower haloalkyl, lower haloalkenyl,
amino, mono- or di-lower alkylamino;
wherein R is selected from amino, hydroxy, alkoxy, or
halogen;
wherein Rs is H or amino; and

described below.

(III)

HN
O

for its removal.

Acyl protecting groups may be removed by Simple
hydrolysis with Strong or moderately strong bases, Such as
alkali metal hydroxides, at temperatures from about the
ambient temperature to about 100° C. Such hydrolyses may
be conveniently carried out in hydroxylic Solvents, espe
cially aqueous alkanols. The reactions may also be carried
out in any convenient Solvent, Such as polyols including
ethylene glycol, etherS Such as tetrahydrofuran and the like,
ketones Such as acetone and methyl ethyl ketone and other
polar Solvents Such as dimethylsulfoxide. The cleavage of
acyl protecting groups may also be performed with other
bases, including, for example, Sodium methoxide, potassium
t-butoxide, hydrazine, hydroxylamine, ammonia, alkali
metal amides and Secondary amines Such as diethylamine
and the like. The acyl protecting groups can also be removed
with acid catalysts, Such as methaneSulfonic acid, hydro
chloric acid, hydrobromic acid, Sulfuric acid, or with acidic
ion eXchange resins. The removal of protecting groups
which are ethers is carried out by known methods, for
example, with ethanethiol and aluminum chloride.
A preferred Synthetic method for preparing compounds
and intermediates according to the present invention is

O

O
40

(CR)

-

H
C-OH.
H

45

C-R

The hydroxy group of the compound of Formula (VI) may

50

wherein R is selected from alkyl, alkenyl, aryl, CHOH,
-CH2-O-alkyl, -CH2-O-aryl, -CHOPOH,
-CH-O-carbohydrate, -CH-NH-peptide, or
-CH-O-peptide;
wherein R is selected from hydroxy, -O-carbohydrate,
-NH-peptide,
O

HN

1. N

NH2

R3

Formula (VII):
(VII)

\N

55

O

(CF2)
60

N21

1. N

be protected with a protecting group to form compounds of

-O-Protecting Group.
65

The furyl group is converted to the carboxyl group by

oxidation, to form compounds of Formula (VIII):

6,013,790
(VIII)
O

(CF2)

OH

C-O

C-O-Protecting Group.

1O

wherein R is alkyl, alkenyl, aryl, CH-OH, CHO-alkyl,
CHO-aryl, CHOPOH, CH-O-carbohydrate, CH-NH
peptide, or CH-O-peptide.
Additionally, essentially any carbohydrate residue or
The carboxyl group of compounds of Formula (VIII) may be 15 amino acid or peptide residue can be introduced at the
reduced to a hydroxymethyl group to form compounds of 1-position to form the compounds of formula (XIII):

Formula (IX):

Carbohydrate

(DX) 20
OH

(CF2)

C-O
25

C-O-Protecting Group.

or Formula (XIV):

H

3O

o1

Peptide

The protecting group of the compounds of Formula (IX)
may be removed to produce compounds of Formula (X):
(X)

35

OH

(CF2)

$

These general procedures are employed in the preparation
of the compounds of the present invention in the Examples
below. Moisture Sensitive reactions were run under a nitro
gen atmosphere using oven dried Schlenk-type glassware.
C-OH.
Commercially available high grade purity reagents were
H
used
without further purification. THF was distilled from Na
45
and benzophenone, CHCl was distilled from CaH2. TEA
and DEA were stored over molecular sieves and KOH,
respectively. Analytical Samples were obtained by prepara
Alternatively, the hydroxy group of the compound of tive TLC using Whatman PK5F silica plates with fluorescent
Formula (IX) may also be protected to form compounds of indicator or by recrystallization. Deuterated chloroform and
Formula (XI):
50 acetone were Stored over basic alumina and filtered through
Sand directly in the Sample tube. Melting points are uncor
40

rected.

(XI)
O-Protecting Group

(CR)

r

55

-

NMR Spectroscopy data is reported in the following
Examples as follows. Since compounds 2, 3, 4, 5, and 7 can
be obtained in high de following the experimental protocol,
and the two cis and trans-1.5 diastereomers cannot be

Separated by Simple column chromatography, the NMR data
are reported for the major diastereomer only. HETCOR,
-O-Protecting Group.

60

COSY, H, C, F, 'F decoupled 'H, H decoupled 'F,
and 'F decoupled 'C experiments were run on a 500 MHz

General Electric instrument. H NMR were also run on a

360 MHZ Tecmag-Nicolet instrument. Standard resolution

enhancement algorithms were applied to the 'H, C, F,
and cross-decoupled spectra. When the assignment of CF
These procedures are general and can be successfully as mutiplicity on the C is complicated by the presence of
used for the introduction of any R-group in the terminal overlapping Signals, and/or low S/n ratio the chemical shift
position. Examples include those shown in Formula (XII):
is given based on 'F decoupled 'C data.

6,013,790
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dark-yellow oil which was a 1:1 mixture of trans:cis-1,5-(2)

The following preparations and examples further illus
trate the Synthesis of compounds of the present invention.
Diethyl 2,2,3,3,4,4-hexafluoropentanoate. Large quanti
ties of commercially available diester was prepared using
Standard esterification procedure from the corresponding

diastereomers. The oil crystallized after Standing undis
turbed for a 2 h period. Recrystallization from an anhydrous,
acid-free 3:1 hexane:CHCl solution afforded X-ray quality
crystals mp=89-90° C. in quantitative yield. The X-ray
Structure revealed that the cis-2 diastereomer had undergone
ring opening and closing to the crystal-forming trans-2 unit.
The X-ray crystal structure determination of 2 is shown in
FIG. 1. The trans-2 racemate is clearly visible in the cen
trosymmetric unit cell. Exclusion of water from the NMR
Solvent prevents the ring opening in Solutions and allows to

diacid. An ethanol Solution (250 mL) containing 2,2,3,3,4,
4-hexafluoroglutaric acid (11.23g, 47.0 mmol) and concen
trated Sulfuric acid (5 mL) was refluxed for 7 days using a
Soxlet apparatus and 4 A activated molecular sieves (1.6 mm
pellets) for water removal. At the end of this period ethanol
was removed in vacuo and the residue was neutralized to pH

7 with NaHCO powder before adding water (250 mL). The

Solution was transferred in a separatory funnel and the

product was extracted with ether (3x100 mL). The combined
ether extracts were washed with water (75 mL), pre-dried
with brine (75 mL), then dried over MgSO and filtered.
After ether removal, the crude pale yellow liquid was
subjected to vacuum transfer (0.5 mmHg, 60-80° C.).

15

NMR of trans-2 (125 MHz, de- Acetone) & 642.2 (ddd,
J-25.9, 18.5, 3.7 Hz), 91.5 (dd, J =38.8, 24.1 Hz),
109.0 (CF), 111.0, 110.8 (CF), 113.9 (CF), 112.6, 143.3,

Diethyl 2,2,3,3,4,4-hexafluoroglutarate was obtained as a

144.3. 'F of trans-2 (470 MHZ, di- Acetone, 'F-'F

clear, low viscosity liquid (11.34g, 81%). H NMR (360
MHz CDC1) & 1.38 (6H, t, J=7.2 Hz), 4.41 (4H, q, J=7.2
Hz).
Ethyl 5-(2-furyl)-5-oxo-2,2,3,3,4,4-hexafluoropentanoate
(1). The following steps were performed in the absence of
light. A solution of furan (0.9 mL, 12.4 mmol), in THF (30
mL) was cooled to -78° C. prior to the addition of n-BuLi
(3 mL, 2.5 M in hexane, 7.5 mmol). The mixture was stirred
at room temperature for 3 h. The resulting 2-lithiofuran
solution was added to a -78 C. solution of diethyl 2.2.3,
3,4,4-hexafluoropentanoate (4.1 g, 13.8 mmol) in THF (100
mL) over a 15 min period and allowed to stir for 30 min.

Warm up and Simultaneous in vacuo removal of Solvent
followed at the end of the stirring period. The yellow-red
crude mixture was immediately purified with column chro
matography on Silica gel. The diester was recovered during
elution with hexanes and a 9:1 hexanes: EtOAc mixture

25

813.9, 65.2, 108.7 (tt, J =266.4, 31.4 Hz, CF.), 110.9 (tt,
J-2266.4, 33.3 Hz, CF), 111.0 (tt, J =266.4, 31.4 Hz,
CF), 113.92, 125.6, 148.5, 151.0, 159.2 (t, J =29.6 Hz),

171.4 (t, J

=27.8 Hz). 'F NMR (470 MHz, CDC1) &

40

45

Found: C, 41.80; H, 2.66.

(1)

\ /

1-O-Benzyloxy-5-(2-furyl)-2,2,3,3,4,4-hexafluorooxane
(3). Benzoyl chloride (1.16 mL, 10.0 mmol) and TEA (3.0
mL, 20 mmol) were added dropwise Simultaneously to a
solution of crystalline 2 (2.32 g, 8.41 mmol) in 50 mL of

CHCl at room temperature. The mixture was stirred at that
temperature for 15 min before quenching with exceSS
diethylamine. After an additional 15 min period the solvent
was removed and the residue was immediately poured onto
a silica gel column and eluted with a 9:1 hexane:EtOAc
mixture. This operation efficiently removed the impurities in
the form of triethylammonium chloride and N,N-diethyl

benzamide giving the clear heavy oil 3 (3.11 g, 97%) as a
50

O

for CHFOs: C, 39.15; H, 2.19. Found: C, 39.25; H, 2.34.

35

-123.40 (2F, s), -118.69 (2F, t, J=10.0 Hz), -116.98 (2F, t,
J=10.0 Hz). Anal. Calcd. for CHFO: C, 41.53; H, 2.53.
O

COSY cross peak) 8 –143.9 (i1, dddddd, J=272.2, 13.8, 9.6,
6.0 Hz), -132.0 (1F, ddt, J=274.2, 10.1, 10.0 Hz), -130.4
(1F, dtddd, J=264.2,9.4, 8.9, 4.71, 1.4 Hz), -128.22 (1F, ddt,
J=264.2, 15.0, 10.0 Hz), -125.6 (1F, ddddd, J=272.2, 7.3
Hz), -121.6 (1F, ddtd, J=274.2, 16.8, 7.0 Hz). Anal. Calcd
(2)

(1.64 g., 39% recovery). The UV active product 1 (1.53 g,
64% cacld from nBuLi), as a yellow oil, eluted with a 8:2

hexanes: EtOAc combination. H NMR (360 MHz, CDC1,
H-'F HETCOR cross peak) & 1.37 (3H, t, J=7.2 Hz), 4.43
(2H, q, J=7.2 Hz), 6.65 (1H, dd, J=3.7, 1.6 Hz), 7.50 (1H,
m), 7.80 (1H, d, J=1.6 Hz). 'C NMR (125 MHz, CDC1)

record spectra of the single anomer. "H NMR of trans-2 (500
MHz, CDC1, H-'FHETCOR cross peak) & 3.60 (1H, s),
5.45 (1H, s), 5.52 (1H, d, J-23 Hz), 6.47 (1H, dd, J=3.2, 2.0
Hz) 6.67 (1H, d, J=3.2 Hz), 7.51 (1H, d, J=1.2 Hz). 'C

purification. H NMR of trans-3 (500 MHz, CDC1) & 5.20

O

CF ls
CE,1 NCF, OEt

1-Hydroxy-5-(2-furyl)-2,2,3,3,4,4-hexafluorooxane (2).
Sodium borohydride (0.35 g, 9.25 mmol) was added to a
stirred solution of 1 (1.53 g, 4.81 mmol) in anhydrous
methanol (100 mL) at 0° C. After a 3 h period at that

(1H, dd, J=20.9, 3.62 Hz), 6.37 (1H, dd, J=15.31, 3.62 Hz),
6.45 (1H, dd, J=3.23, 1.62 Hz), 6.70 (1H, d, J=3.23 Hz), 7.50

55
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temperature, the Solvent was removed using a rotoevapora
tor and the residue acidified to pH 2 with 2N HC1. The
aqueous mixture was then neutralized with Saturated

NaHCO prior to an extraction with ether (3x50 mL). The
combined organic layers were dried with MgSO and con
centrated. Product 2 (1.28 g., 96%) was obtained as a viscous

15:1 mixture of tris:cis 1,5-disubstituted oxane by NMR.
The mixture was carried to the next step without further

65

(3H, m), 7.64 (1H, m), 8.13 (2H, dd, J=8.06, 1.21 Hz). 'C

NMR of trans-3 (125 MHz, CDC1) & 70.53 (ddd, J =
22.2, 18.5, 3.7 Hz), 88.7 (ddd, J =29.6, 18.5, 5.6 Hz),
109.0 (ddtt, J =283.0, 253.4, 29.6, 22.2 Hz, CF.), 110.5
(ddddd, J =268.2, 260.8, 27.8, 24.0, 3.7 Hz, CF.), 111.0,
111.6 (ddddd, J =268.2, 260.8, 27.7, 24.0, 3.7 Hz, CF)
112.7, 127.4, 128.7, 130.5, 134.6, 1424, 144.5, 163.5. 'F
NMR of trans-3 (470 MHz, CDC1) 8 –145.9 (1F, ditt,
J=274.7, 15.3, 4.4 Hz), -137.0 (1F, dtd, J=263.8, 17.4, 8.7
Hz), -133.6 (1F, ddt, J=261.6, 15.3, 8.7 Hz), -130.3 (1F, dm,
J=266.4 Hz),429.0 (1F, ddt, J=265.9, 13.1, 10.9 Hz), -126.9
(1F, dim, J-272.7 Hz). Anal. Calcd. for CHFO: C,
50.54; H, 2.65. Found: C, 50.76; H, 2.48.

6,013,790
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added to the reaction mixture at room temperature and
stirred for 30 min. The reaction was quenched with HO (20
mL) at 0°C., treated with 20 mL 2M HCl, then neutralized
with NaHCO, before extraction with EtOAc (3x150 mL).
The organic extracts were dried with MgSO, filtered and
concentrated. The crude clear heavy oil was purified by flash
chromatography on Silica with a 10:1 mixture of hexane
:ethyl acetate. Pure 5 (1.814g, 82%) was obtained as a pale

(3)

yellow solid. "H NMR (500 MHz, CDC1) & 2.05 (1H, dd,

5-O-Benzyloxy-2,2,3,3,4,4-hexofluorooxanoic acid (4).
Oxidative removal of furyl was effected using RuO (5 mol
%) that was added to a biphasic solution of water (180 mL),
acetonitrile (60 mL), and CC1 (120 mL) containing 3 (2.93
g, 7.71 mmol) and NalO (24.7 g., 116 mmol). The grey

15

J=8.5, 5.2 Hz), 4.02 (2H, m), 4.19 (1H, ddddd, J=20.1, 3.6
Hz), 6.20 (1H, dd, J=11.3, 3.6 Hz), 7.50 (2H, m), 7.66 (1H,
m), 8.13 (2H, m). 'C NMR (125 MHz, CDC1) & 558.3,
74.6 (dd, J =27.7, 24.0 Hz), 88.7 (ddd, J =29.6,
18.5, 5.5 Hz), 108.5 (ddtt, J =283.0, 253.4, 29.6, 20.3 Hz,
CF), 110.4 (dddd, J =270.1, 264.5, 27.7, 24.0 Hz, CF),
112.2 (dddd, J =270.1, 264.5, 27.7, 24.0 Hz, CF), 127.3,

128.8, 130.4, 134.7, 163.7. 'F (470 MHz, CDC1) 8-146.7

(1F, ditt, J=273.3, 13.9, 9.7 Hz), -137.1 (1F, dddt, J=262.2,
15.3, 8.3, 2.8Hz), -134.0 (1F, dim, J=262.2 Hz), -132.4 (1F,
ddtd, J=267.7, 13.9, 6.9, 4.2 Hz), -131.5 (1F, dim, J=266.4
Hz), -127.2 (1F, dim, J=269.1 Hz). Anal. Calcd. for

mixture was stirred vigorously for 5 days while monitored
by TLC. The volatile solvents were removed and the aque

CHFO: C, 45.36; H, 2.93. Found: C, 45.47; H, 2.91.

ous residue extracted with EtOAc (3x150 mL) and dried

with MgSO, filtered through celite and activated carbon.
Solvent removal in vacuo cleanly afforded 4 as a white solid

(2.65 g, 96% wet yield). H NMR (500 MHz, de-Acetone)

(5)
25

83.6 (broad S, OH), 5.48 (1H, dmult, J=21.4 Hz), 6.59 (1H,
dd, J=14.9, 3.62 Hz), 7.62 (2H, m), 7.78 (1H, m), 8.12 (2H,
m). Anal. Calcd. for CHFOs: C, 45.59; H, 2.25. Found:

C, 43.00; H, 2.25. The elemental analysis data shows the
presence of H2O even after extensive drying. A Small
amount of the hygroscopic acid product was quantitatively
converted into the methyl ester derivative methyl 5-O-

benzyloxy-2,2,3,3,4,4-hexafluorooxanoate (4a) by standard

titration with diazomethane in ether Solution, and then fully

characterized. "H NMR of 4a (500 MHz, (CDC1) & 3.87
(3H, s), 4.71 (1H, m), 6.25 (1H, dd, J=14.5, 3.63 Hz), 7.50
(2H, m), 7.66 (1H.m), 8.12 (2H, m). 'C NMR of 4a (125

35

1-Hydroxy-5-(5'-hydroxymethyl)-2,2,3,3,4,4hexafluorooxane (6). A solution of 5 (0.497 g, 1.44 mmol)
and KCO (65 mg, 0.47 mmol) in trifluoroethanol (20 mL)

MHz, CDC1) & 53.6, 72.1 (t, J =25.9 Hz), 88.2 (ddd,
J-22.2, 18.5, 3.7 Hz), 108.5 (ddtt, J =281.2, 253.4,
29.6, 20.3 Hz, CF), 110.1 (tdd, J =266.4, 29.6, 22.2 Hz,
CF), 111.2 (tdd, J =257.1, 25.9, 20.5 Hz, CF), 127.2,

40

CDC1) 8 –145.4 (1F, ddduart, J=273.6, 12.7 Hz), -136.8
(1F, dddtd, J=261.0, 14.7, 7.5, 2.4 Hz), -133.6 (1F, dddt,
J=263.0, 15.4, 9.3, 5.8 Hz), -128.1 (2F, m), -126.7 (1F, dim,
J=273.6 Hz). HRMS (El) m/z calcd for CHFOs

45

128.8, 130.6, 134.7, 1617, 163.4 °F NMR (470 MHz,

372.0432, found 372.0434.

(4)

50

was stirred at room temperature for 12 h. After solvent
removal, Saturated NaHCO Solution was added to the
residue. The aqueous layer was extracted with pentane

(3x50 mL) then acidified to pH 2 with 2N HCl followed by
extraction with AcOEt (3x60 mL). The AcOEt extract was
dried with MgSO and concentrated to yield 6 (0.347g, 99%
crude) as a colorless heavy oil which crystallized during in

vacuo removal of Solvent. The product was recrystallized
from a 2:1 hexanes: EtO solution. The normal protocol
followed in the NMR sample preparation was not sufficient
to prevent equilibration of the cis and trans diastereomers in
Solution. Qualitatively, compound 6 was Soluble in acetone,
EtOAc, ether, and water; insoluble in CHCl and other

solvents of lower polarity. H NMR of cis 1.5-(6) (500 MHz,
d-Acetone, 'H-'F HETCOR cross peaks) & 3.82 (1H,

55

60

1-O-Benzyloxy-5-(5'-hydroxymethyl)-2,2,3,3,4,4hexafluorooxane (5). A solution of 4 (2.3 g., 6.42 mmol) in
THF (20 mL) at 0° C. was treated with 1M BH-THF
complex (39 mL). The mixture was stirred at 0° C. for 20
min, then at room temperature for 24 hr in a closed System.

At the end of that period 1 MDIBAL-H in THF (19 mL), was
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dddd, J=12.1 6.9, 5.7, <0.5 unres. Hz), 3.95 (1H, dddd,
J=12.1, 6.5, 4.0, 1.2 Hz), 4.18 (1H, ddtt, J=23.5, 7.0, 5.3, 1.4
Hz), 4.35 (1H, dd, J=6.7, 5.7 Hz, 5'-OH), 5.31 (1H, dddd,

J=15.7, 8.5, 4.4, 0.8 Hz), 7.34 (1H, d, J=8.3 Hz, 1-OH). H
decoupled 'C NMR of cis 1.5-(6) (125 MHz, CDC1) & 58.3
(d, J-6.5 Hz), 74.2 (dd, J-26.8, 22.2 Hz), 92.2
(ddd, J =27.7, 19.4, 4.62 Hz). 'F decoupled 'C NMR
of cis 1.5-(6) (125 MHz, CDC1) & 109.7(CF), 111.6 (CF),
113.5(CF). 'F of cis 1.5-(6) (470 MHz.d-Acetone, 'F'F COSY cross peak) 8 –145.5 (1F, ddddtd, J=270.7, 14.7,
14.0, 9.3, 0.8 Hz), -139.4 (1F, ddddddd, J=261.1, 16.1, 14.8,
7.6., 1.42 Hz), -132.8 (1F, ddtd, J=267.5, 15.5, 9.3, 1.3 Hz),
-131.7 (1F, ddddddd, J=264.5, 15.4, 13.8, 8.1, 1.4, 0.5 Hz),
-130.4 (1F, ddtdd, J=264.5, 12.3, 9.4, 1.4, 0.8 Hz), -125.3

6,013,790
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(1F, dddd, J-270.7, 13.9, 7.9, 40 Hz). "H NMR of trans
1.5-(6) (500 MHz, de-Acetone, 'H-'F HETCOR cross

(7)

peak) & 3.80 (1H, dddd, J=12.1, 6.9, 5.7, <0.5 unres. Hz),
3.96, (1H, dddd, J=12.1, 6.5, 4.0, 1.2 Hz), 4.24 (1H, t, J=6.3
Hz, 5'-OH), 4.52(1H, d unres.m., J=24.8 Hz), 5.55 (1H, dt,

J=7.3, 6.0 Hz), 7.36 (1H, dt, J=5.6, 21 Hz, 1-OH). H
decoupled 'C NMR of trans 1.5-(6) (125 MHz, CDC1) &
58.2 (d, J

91.6 (ddd, J

=4.6 Hz), 69.1 (dd, J

=26.8, 21.3 Hz),

=36.1, 23.1, 2.8 Hz). 'F decoupled 'C

NMR of trans 1,5-(6) (125 MHz, CDC1) & 109.0(CF),

111.2 (CF), 113.5(CF) 'F of trans 1.5-(6) (470 MHz,
d-Acetone, 'F-'F COSY cross peak) 8 –143.9 (1F,
dddddd, J=269.5, 12.8, 10.0.8.0, Hz), -131.2 (1F, dtddd,
J=263.2, 16.3, 12.6, 7.8, 1.7 Hz), -130.7 (1F, ddtdt, J=268.5,
11.6, 3.7, 1.8, 1.0, 0.5 Hz), -129.3 (1F, ddddd, J=263.2,
13.2, 9.8, 8.0, 1.8, 0.8 Hz), -123.4 (1F, dddtdd, J=269.4,
15.1, 13.2, 7.5, 2.6, 2.1 Hz), -120.7 (1F, ddddddd, J=268.5,
16.4, 15.4, 8.2, 7.3, 1.7, 0.9 Hz). Anal. Calcd. for CHFOs:

15

By following the same procedures as above, but employ
ing the corresponding 2,2,3,3-tetrafluorodiethylbutanedioate
as the Starting material, the following compounds were
made:

C, 30.01; H, 2.52. Found: C, 29.97; H, 2.44.
(6)
25

(cis)-1-hydroxy-4(2-furyl)-2,2,3,3-tetrafluorofuran

1-O-Benzyloxy-5-(5'-O-Benzyloxymethyl)-2,2,3,3,4,4hexafluorooxane (7). Compound 7 (134 mg., 93%) was

35

obtained as a pale yellow Solid following the Same method

as for 3 using alcohol 5 (113 mg, 0.32 mmol) or diol 6. The
usual workup protocol followed by column chromatography
and preparative TLC with 7:1 hexane:EtOAc as the eluent
gives the product which is used for chiral Separation. The
X-ray crystal structure determination for 7 is shown in FIG.

F
40

F

(trans)-1-hydroxy-4(2-furyl)-2,2,3,3-tetrafluorofuran
HO

2. "H NMR (500 Mhz, CDC1 & 4.50 (1H, dim, J-21.8 Hz),
4.61 (1H, dd, J= 12.1, 6.9 Hz), 4.78 (1H, dd, J=12.1, 40 Hz),
6.25 (1H, dd, J=14.9, 3.6 Hz), 7.45 (2H, m), 7.50 (2H, m),

45

7.59 (1H, m), 7.66 (1H, m), 8.03 (2H, m). 'C NMR (125

MHz, CDC1) & 59.5, 71.9 (dd, J =27.8, 24.1 Hz), 88.5
(ddd, J =29.6, 18.5, 5.6 Hz), 108.5 (CF), 110.4 (CF),
112.2 (CF), 127.3, 128.4,128.5, 128.8, 129.9, 130.5, 133.5,

B-2,3-dideoxy
50

HO

1346, 1634, 1659. 'F (470 MHz, CDC1) 8 -127.2 (1F, d

unres.m., J=277.2 Hz), -130.4 (1F, ddtd, J=256.6, 9.9, 3.3
Hz), -132.3 (1F, ditt, J=267.3, 8.3 Hz), -133.8 (1F, ddt,
J=262.3, 24.7, 8.3 Hz), -137.0 (1F, ddtd, J=262.3, 16.5,
14.9, 6.6 Hz), -146.2 (1F, d unres.m, J-273.9 Hz). Anal.

2,2,3,3-tetrafluororibofuranose

OH

55
F

F

C-2,3-dideoxy

Calcd. for CHFOs: C, 53.58; H, 3.15. Found: C, 53.24;

2,2,3,3-tetrafluororibofuranose

H, 3.19.
60
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Compounds of the present invention are prepared accord
ing to the following Scheme.

-continued

O

O

i), ii), iii)

He

F

F

BzOCH2
1O

(cis)-1-(9-(6-methoxypurinyl)-4(1-butyl)-2,2,3,3-tetrafluorofuran

O

O

F

F

F

F

iv), v), vi)

BzOCH2
15

Base
F

F

F

i) Benzyl-O-CHZnBr, THF, -78 °C
ii) NaBH4, 50% aq. MeOH, NaHCOs

N

N

O
F

N

DCC or POCl3
DIBAL-H

NN

v) MsC1, EtsN, CHCl2
Silyated Base, Nal/CH3CN

2N
OMe

(trans)-1-(9-(6-methoxypurinyl)-4(1-butyl)-2,2,3,3-tetrafluorofuran

25

35

(cis)-1-(9-(6-aminopurinyl)-4(1-butyl)-2,2,3,3-tetrafluorofuran

40

N

N

n
45

NN

2N

(trans)-1-(9-(6-aminopurinyl)-4(1-butyl)-2,2,3,3-tetrafluorofuran

In an alternative embodiment according to the present
invention, Starting materials for the process of the present
invention of the following formula may be used:

50

55

60

and a new reagent, benzyloxymethylzinc bromide, is used
for introducing the 5'-hydroxymethyl moiety. This key
reagent enables these inexpensive materials to be homolo
gated to the proper number of carbon atoms in the ribose
unit.
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The hexose Sugar analogs according to the present inven
tion are Similarly prepared from the corresponding perfluo
roglutaric anhydride.
The heavily fluorinated nucleoside analogs of the present
invention may be used for the treatment of viral infections
in the manner usual in the treatment of Such pathologies. The
compounds may be effective for the treatment of viral
infections in general, and particularly in the treatment of
infections caused by retroviruses, such as HIV.
The compounds may be effectively administered orally,
topically or parenterally. In general, dosages in the range of
from about 0.05 mg/kg to about 5000 mg/kg are useful,
preferably in the range of from about 5 mg/kg to about 500
mg/kg.
The compounds may be used in medicine in the form of
conventional pharmaceutical compositions. The formulation
of the compositions is conventional, and follows the usual
practices of pharmaceutical chemists. When a heavily flu
orinated nucleoside analog of the present invention is to be
administered topically, it is formulated as a topical
composition, Such as a cream or ointment to be rubbed into
the affected tissue. Creams are emulsions of an oily phase
and an aqueous phase, in which the heavily fluorinated
nucleoside analogs are dissolved or Suspended. Ointments
are greasy or waxy compositions, in which the nucleoside
may be soluble but may be suspended, if it is insoluble at the
desired concentration. Topical formulations preferably fur
ther include a transdermal agent, Such as DMSO, propylene
glycol, or the like.
Parenteral compositions may be preferably formulated in
Such a way that the heavily fluorinated nucleoside can be
dissolved for injection. Alternatively, the heavily fluorinated
nucleoside may be formulated as a dried powder with
physiologically-acceptable Suspending agents, Such as
Starch, Sugar and the like, to which Sterilized water is added
to form a Suspension to be injected. Parenteral compositions
can be formulated in aqueous bases containing moderate
amounts of physiologically-acceptable Solvents, Such as
propylene glycol and the like, and Such compositions may be
capable of dissolving the present heavily fluorinated nucleo
Side analogs at acceptable concentrations.
A great many types of orally administered compositions
are in common use, including unit dosage forms Such as
tablets and capsules, and liquid dosage forms Such as

6,013,790
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Suspensions. In general, unit dosage forms are preferred in
pharmacy and are formulated in Such a way as to provide the
usual dose in one or a Small number of tablets or capsules.
The formulation of tablets, making use of appropriate
lubricants, binding agents and disintegration agents, is and
long has been thoroughly understood by pharmaceutical
chemists. The formulation of capsules involves only the
dilution of the heavily fluorinated nucleoside analogs with
an appropriate proportion of an inert powdery Substance,
Such as lactose, to provide the proper bulk to fill the desired
Size of capsule.
The description above should not be construed as limiting
the Scope of the invention, but as merely providing illustra
tions to some of the presently preferred embodiments of this
invention. In light of the above description and examples,

2. The compound according to claim 1 wherein R is

various other modifications and variations will now become

3. The compound according to claim 2 wherein
15

What is claimed is:

25

R1
F

O
F

F

F

4. The compound according to claim 3 wherein

is

methyl.

apparent to those skilled in the art without departing from
the Spirit and Scope of the present invention as defined by the
appended claims. Accordingly, the Scope of the invention
should be determined Solely by the appended claims and
their legal equivalents.

F

is

lower alkyl.

R2

5. The compound according to claim 3 wherein
is
ethyl.
6. The compound according to claim 2 wherein is
lower halo alkyl.
7. The compound according to claim 6 wherein
is
trifluoromethyl.
8. The compound according to claim 2 wherein
is
bromoethenyl.
9. The compound according to claim 2 wherein is
monoloweralkylamino.
10. The compound according to claim 9 wherein R is
methylamino.
11. The compound according to claim 2 wherein R
halogen.
12. The compound according to claim 11 wherein R is
iodo.

13. The compound according to claim 11 wherein R is

F

fluoro.

14. The compound according to claim 1 wherein R is
wherein R is Selected from alkyl, alkenyl, aryl, -CH2
O-alkyl, -CH-O-aryl, -CHOPOH, -CH-Ocarbohydrate,
wherein R is selected from hydroxy, -O-carbohydrate,
O

40

NH2.
45

NH2

1.

es N

R4

N

1st

O

HN

N21

N4

50

O

s

N

N

HN

Or

1s,

N

55

R4

Na

Rs

N

60

wherein R is Selected from H, halogen, lower alkyl,
lower alkenyl, lower haloalkyl, lower haloalkenyl,
amino, mono- or di-lower alkylamino;
wherein R is Selected from amino, hydroxy, alkoxy, or
halogen; and
wherein Rs is H or amino, including all Stereoisomers
thereof.
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16. The compound according to claim 15 wherein R is
hydroxy.
17. The compound according to claim 15 wherein R is
amino.

6,013,790
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18. The compound according to claim 1 wherein R is

22
(VI)

O

\N

N

HN
Rs

N

lsN

O

5

N

(CF2)
1O

19. The compound according to claim 18 wherein Rs is

C-OH
H

amino.

20. The compound according to claim 18 wherein Rs is H.

21. The compound according to formula (II):

15
II

R1
F
F

(c) protecting the hydroxy group of the compound of
Formula (VI) to form compounds of Formula (VII):

o,F is

(VII)

N

2O
F
F

O

F

(CF2)

wherein R is selected from alkyl, alkenyl, aryl,
-CH-OH, -CH2-O-alkyl, -CH2-O-ary 1, 25
–CHOPOH:
wherein R is Selected from hydroxy,
O

-O-Protecting Group

NH2
3O

(d) oxidatively removing the furyl group from the com
pound of Formula (VII) to produce compounds of
Formula (VIII):

R

HN

3

N21

1.

es.

R4

N21

ls

35

(VIII)

O
N

N

N

N

HN

ls

N

N

N

Rs

(CR)

N

st-

40

N
N

Or

-O-Protecting Group

wherein Rs is selected from H, halogen, lower alkyl, as

lower alkenyl, lower haloalkyl, lower haloalkenyl,
amino, mono- or di-lower alkylamino;
wherein R is Selected from amino, hydroxy, alkoxy, or
halogen; and

wherein
Rs is H or amino; including all stereoisomers so
thereof.

(e) reducing the carboxyl group of the compound of
Formula (VIII) to a hydroxymethyl to form compounds
of Formula (IX):
(DX)

22. A process for preparation of a heavily fluorinated
Sugar derivative comprising the Steps of:

(a) converting one of the carboxylic ester groups of
Formula (IV):
loweralkyl-O-C(O)-(CF)-C(O)-O-loweralkyl

OH

(CF2)
55

(IV)

wherein n=2 or 3, to the ketone to yield compounds of

Formula (V):
2-furyl-C(O)-(CF)-C(O)-O-loweralkyl

r

5-O-Protecting Group.
60

(V)

(b) contacting a compound of Formula (V) with a reduc
ing agent to form compounds of Formula (VI):

23. The process according to claim 22, further comprising
the Step of removing the protecting group of the compound

of Formula (IX) to produce compounds of Formula (X):

6,013,790
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(X)

OH

(XI)

O-Protecting Group

(CE)

--O

5

r
(CR)

C-OH.

-

1O

-O-Protecting Group.
24. The process according to claim 22, further comprising

the Step of protecting the hydroxy group of formula (IX) to
form compounds of Formula (XI):

k

.

.

.

.

